Tue-26-12-2017, 18:44 PM
(Tue-26-12-2017, 18:22 PM)Caroline Wrote:(Tue-26-12-2017, 17:14 PM)Maryam Wrote: Tnx all, I found an interesting article which compaired the 1st, 2nd and 3th generation bio’s and it seems that the ones targeting IL17 have a faster onset of action. They also “aim higher”. Apperently the first two generations were aimed for 75% reduction as demand, whereas the 3th they want to aim at 100%, which is really interesting
IL-17 is the Psoriatic Arthritis interleukine, i am simplifyiing now. But you can expect the best working for your PsA, which doesn’t mean it does not work for your Psoriasis, but you can expect less. There is quite some experience now on the forum that suggests this.
That is indeed a bit simplefied, especially when you read that the makers of these bio’s aimed for clearance for the skin also. And a lot of people who start a IL17 bio see results within two weeks. The pathways of these interleukines are very complicated and somehow connected, apperently tremfya was developed because they’ve found that blocking IL12 besides IL23 is obsulete.
I am really curious if they will find one interleukine in specific